Autophagy
Retro Biosciences’ $1.8 Billion Bet Moves From Ambition to Clinical Risk
A new financing values Retro at $1.8 billion before the round. Its first clinical program makes the scientific and execution risks easier…
Science. Medicine. Technology. Living longer.
A new financing values Retro at $1.8 billion before the round. Its first clinical program makes the scientific and execution risks easier…